GleamWall
中文EN

OTLK Outlook Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1649989 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-40.7%
TTM EPS YoY16.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin195.6%
Operating margin4,781.8%
Net margin5,253.5%
FCF margin—
EBITDA margin4,772.9%

Returns

ROE—
ROA-251.7%
ROIC (approx.)—
Asset turnover-0.05x

Leverage & solvency

Liabilities / assets139.7%
Debt / equity—
Current ratio0.81x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-20.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-09-30FY20242024-09-30
Income statement
Revenue$1.41M—
Cost of revenue$1.36M—
Gross profit$57,205—
R&D expense$27.18M$41.76M
SG&A expense$39.94M$29.94M
Operating income-$67.06M-$71.70M
Interest expense—$3.16M
Pretax income-$63.98M-$75.36M
Income tax-$1.55M$2,800
Net income-$62.42M-$75.37M
EBITDA-$66.94M-$71.59M
EPS (basic)-1.79-4.06
EPS (diluted)-1.79-4.06
Weighted avg. shares (diluted)34.80M18.55M
Banking
Net interest income-$283,128-$3.16M
Balance sheet
Cash & equivalents$8.08M$14.93M
Receivables$1.49M—
Inventory$3.34M—
Current assets$17.39M$27.42M
Total assets$18.58M$28.82M
Current liabilities$45.81M$42.55M
Total liabilities$50.77M$101.90M
Shareholders' equity-$32.19M-$73.08M
Shares outstanding53.89M23.91M
Cash flow statement
Operating cash flow-$51.83M-$68.79M
Financing cash flow$44.98M$60.33M
Depreciation & amortization$117,052$113,859
Stock-based compensation$8.90M$5.39M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.